| Field | Specification |
|---|---|
| Target | |
| Alternative names | ADP-sugar pyrophosphatase; 8-oxo-dGDP phosphatase; Nuclear ATP-synthesis protein NUDIX5; Nucleoside diphosphate-linked moiety X motif 5; Nudix motif 5; hNUDT5; YSA1H; NUDT5; NUDIX5 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human NUDT5 recombinant protein (Position: M1-F219). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets ADP-sugar pyrophosphatase (gene NUDT5) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF, flow cytometry, immunoprecipitation and ELISA. The predicted molecular weight is 24.3 kDa, and the supplier reports an observed band at about 35 kDa.
NUDT5 is a Nudix hydrolase that breaks down ADP-ribose and other ADP-sugars. In the nucleus, in the presence of diphosphate, it can instead convert ADP-ribose into ATP, supplying local energy for chromatin remodeling and gene regulation, and it is studied in hormone signaling, nucleotide metabolism and cancer.
| Target | ADP-sugar pyrophosphatase (gene NUDT5; UniProt Q9UKK9, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 24.3 kDa |
| Observed MW | 35 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human, Mouse, Rat) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Immunoprecipitation | 0.5–2 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human Caco-2 cells, human 293T cells, human Jurkat cells, human HepG2 cells, rat liver tissue, rat RH35 cells, mouse liver tissue, mouse HEPA1/6 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human liver cancer tissue, mouse liver tissue, rat liver tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with a confirmed signal (flow cytometry): Caco-2 cells.
Immunogen
Recombinant human NUDT5 fragment (Met1–Phe219), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places ADP-sugar pyrophosphatase in the nucleus. Tissue expression noted by UniProt (human): Widely expressed. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
